Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares (UPSURGE)

This study has been terminated.
Information provided by (Responsible Party):
Regeneron Pharmaceuticals Identifier:
First received: October 12, 2011
Last updated: September 27, 2013
Last verified: November 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: June 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 27, 2013